Stem Cells and Liver Archives
Fast Growing Stem Cells Found In Wisdom Teeth
It was quite a long time ago since we looked at stem cells and teeth. The focus here is a little different as these stem cells derived from cells within teeth are being used to differentiate into either bone or liver tissue.
The National Institute of Advanced Industrial Science and Technology's Research Institute (AIST) for Cell Engineering is working with a team of researchers from Osaka University in Japan and have succeeded in repairing damaged liver and bones in rats by injecting stem cells derived from wisdom tooth germ.
...Continue reading "Fast Growing Stem Cells Found In Wisdom Teeth"
Posted on March 10, 2006 11:48 PM | Comments (0)
New MultiCell/Thomas Jefferson University Research Collaboration to Evaluate Cell Lines for Hepatitis C Treatment
LINCOLN, R.I., Oct. 20, 2005 – MultiCell Technologies, Inc. (OTCBB: MCET), announced today that the Company has entered into a research collaboration with Thomas Jefferson University, Philadelphia's premier medical and health sciences university, to evaluate the Company's immortalized human hepatocytes as model systems to identify new drugs to treat hepatitis C viral (HCV) infection.
...Posted on October 23, 2005 03:53 PM | Comments (0)
MultiCell Enters into a Joint Venture with Living Cell Technologies
MultiCell Enters into a Joint Venture with Living Cell Technologies to Develop Adult Liver Cell Technologies for Drug Discovery, Protein Production and Therapeutic Clinical Applications
LINCOLN, RI – Tuesday, October 4, 2005 – MultiCell Technologies, Inc. (OTCBB: MCET), a leading adult stem cell company and supplier of immortalized non-tumorigenic human hepatocytes for drug discovery and Living Cell Technologies Limited (LCT), a developer of injectable live cell therapy products to treat life threatening diseases, announced today that the parties have entered into a joint venture to develop therapeutic liver cell applications.
...Continue reading "MultiCell Enters into a Joint Venture with Living Cell Technologies"
Posted on October 23, 2005 03:10 PM | Comments (0)
MultiCell and XenoTech to Exhibit Immortalized Hepatocytes at New European Exhibition
LINCOLN, R.I.--(BUSINESS WIRE)--Jun 9, 2005 - MultiCell Technologies, Inc. (OTCBB: MCET) a leading supplier of immortalized human hepatic cell lines for pharmaceutical candidate optimization, announced today that it will attend the inaugural Pharmaceutical Sciences Fair and Exhibition in Nice, France, June 12-17, 2005.
The International Society for the Study of Xenobiotics (ISSX), together with the European Federation for Pharmaceutical Sciences (EUFEPS) and a number of other scientific societies, will co-host the event, which is expected to be sold out.
...Posted on June 9, 2005 08:43 PM | Comments (0)
Doctors Report Regrowing Patient's Livers From Stem Cells
Doctors in the UK are announcing that they have made a significant breakthrough using patients' own stem cells to regrow their own livers. This obviously adds to the hope that one day, researchers could develop methods of replacing organ transplant procedures in future.
Six weeks ago stem cells were extracted from the blood of five human volunteers, and were then injected back into the patient's livers. Early results show that inside the patients' livers, the cells have already started to grow.
...Continue reading "Doctors Report Regrowing Patient's Livers From Stem Cells"
Posted on May 30, 2005 03:14 PM | Comments (0)
Icoria to Profile Liver Progenitor Stem Cells for Vesta Therapeutics
RESEARCH TRIANGLE PARK, N.C., April 27 /PRNewswire-FirstCall/ -- Icoria Inc. (Nasdaq: ICOR) today announced that it has entered into a research agreement with Vesta Therapeutics, Inc. to use Icoria's metabolomics and gene expression technologies to develop biological profiles for Vesta's adult human liver derived stem/progenitor cells and to aid in characterizing the cells' ability to regenerate new liver tissue.
Vesta will use the information generated by Icoria to optimize its
selection of liver cells for transplantation and to guide clinical trials. Biomarkers identified by this research may also be used to help stimulate the differentiation of liver stem and progenitor cells along the hepatic lineage. In return, Icoria will gain access to clinical liver samples for use in validating biomarkers and drug targets in Icoria's proprietary drug and diagnostics discovery research.
Continue reading "Icoria to Profile Liver Progenitor Stem Cells for Vesta Therapeutics"
Posted on May 3, 2005 03:30 PM | Comments (0)
U.S. Patent Office Grants MultiCell Technologies New Liver Stem Cell Patent
MultiCell Technologies, Inc. (OTCBB: MUCL), an innovator in liver cells, announced today that the U.S Patent Office granted MultiCell US Patent Number 6,872,389 for its liver stem cell invention of Dr. Ronald Faris, MultiCell's Chief Science Officer. This patent contains 24 claims to a method of obtaining a population of liver cell clusters. The Company's previous US liver stem cell patent 6,129,911, issued October 10, 2000 contains 50 claims to an isolated liver cluster, a primary liver stem cell, and a method of obtaining an isolated liver stem cell.
...Continue reading "U.S. Patent Office Grants MultiCell Technologies New Liver Stem Cell Patent"
Posted on April 19, 2005 06:58 PM | Comments (0)
Embryonic Stem Cells Treated With Growth Factor By Researchers in North Carolina Reverse Hemophilia
UNC at Chapel Hill researchers have recently made a discovery that may have implications for the treatment of liver-based genetic defects such as hemophilia A and B in humans.
Mouse embryonic stem cells that were treated in culture with a growth factor and then injected into the liver reverse a form of hemophilia in mice analogous to hemophilia B in humans. The report of the study appears in the journal Proceedings of the National Academy of Sciences from Feb. 15th.
The genetically altered mice lack the clotting substance factor IX, which in humans results in the hereditary bleeding disorder known as hemophilia B. This disease, much less common than hemophilia A, affects roughly one of every 35,000 people, primarily males.
...Posted on March 1, 2005 07:31 PM | Comments (0)
Embryonic Stem Cells Treated with Growth Factor Reverse Hemophilia in Mice
University of North Carolina at Chapel Hill researchers have made a discovery that may have implications for the treatment of liver-based genetic defects such as hemophilia A and B in humans.
Mouse embryonic stem cells treated in culture with a growth factor and then injected into the liver reverse a form of hemophilia in mice analogous to hemophilia B in humans, the new study shows.
The genetically altered mice lack the clotting substance factor IX, which in humans results in the hereditary bleeding disorder known as hemophilia B. This disease, much less common than hemophilia A, affects roughly one of every 35,000 people, primarily males...
...Continue reading "Embryonic Stem Cells Treated with Growth Factor Reverse Hemophilia in Mice"
Posted on February 16, 2005 12:37 AM | Comments (0)
Stem Cells Could Reverse Cirrhosis of the Liver
London's Hammersmith Hospitals team in a test, will use a patient's own bone marrow stem cells to treat Cirrhosis. New Scientist magazine also reports on a Japanese team looking at using the treatment for liver fibrosis....This is a massive step towards moving away from liver transplants ... which are touchy at best.... Read On
...Continue reading "Stem Cells Could Reverse Cirrhosis of the Liver"
Posted on December 21, 2004 12:13 PM